Long dsRNA Design for Immune-Efficient Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing RNAi technologies face challenges in efficiently silencing gene expression in mammalian cells without triggering an antiviral immune response, particularly when using longer double-stranded RNAs, which often induce interferon expression and are less effective in targeting multiple mRNA sequences simultaneously.
Innovation Solution
Development of long double-stranded RNAs (ldRNAs) with lengths of at least 40 to 200 base pairs, optionally with 3' overhangs, that are designed to be blunt or have dinucleotide overhangs, reducing recognition by pattern recognition receptors like RIG-I and minimizing antiviral response activation, allowing for efficient silencing of multiple mRNAs or mRNA regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If long double-stranded RNAs (greater than 21 bp) are used to enhance RNAi potency and target multiple mRNAs, then gene silencing efficiency is improved, but antiviral immune response is activated
Solution Approach 1:
The patent applies parameter changes by modifying the structural parameters of dsRNA molecules - specifically using lengths of 25-30 bp (optimal balance between potency and immune activation), adding 3' overhangs of 1-5 nucleotides, and controlling 5' phosphorylation states. These parameter modifications enable long dsRNAs to achieve enhanced gene silencing efficiency while minimizing interferon response activation in mammalian cells.
Solution Approach 2:
The patent applies local quality by creating non-uniform structural features at specific locations of the dsRNA molecule. The 3' overhangs are added only at the terminal regions, while the central duplex region maintains standard base pairing. This localized structural differentiation allows the molecule to be recognized as a legitimate Dicer substrate while avoiding immune detection patterns.
2Productivity
If dsRNA length is increased to 27 bp or more to improve silencing potency, then RNAi activity is enhanced, but interferon expression is induced in immune-sensitive cells
Solution Approach 1:
The patent systematically varies key parameters including dsRNA length (25-30 bp optimal range), 3' overhang length (1-5 nucleotides), and 5' end modifications (phosphorylation or hydroxyl groups). These parameter optimizations enable the dsRNA to maintain high RNAi activity while falling below the threshold for immune system activation, particularly in immune-sensitive cell lines.
Solution Approach 2:
The patent designs dsRNA structures that copy the natural Dicer substrate features - specifically the 3' overhangs and length characteristics - that are normally produced by Dicer processing of viral or endogenous RNAs. By replicating these natural features, the synthetic dsRNAs are recognized as legitimate cellular substrates rather than foreign invaders, avoiding immune activation.
3Object-affected harmful factors
If conventional 21-mer siRNAs are used to avoid immune activation, then antiviral response is minimized, but gene silencing potency is reduced compared to longer duplexes
Solution Approach 1:
The patent merges the advantages of both short siRNAs (immune compatibility) and long dsRNAs (enhanced potency and multi-targeting) into a single optimized structure. The 25-30 bp dsRNAs with 3' overhangs combine the length benefits for potency with the structural features that maintain immune compatibility, effectively merging previously mutually exclusive properties.
Solution Approach 2:
The patent creates dsRNA molecules with universal applicability that can function both as potent gene silencers and as immune-compatible therapeutics. The standardized 25-30 bp structure with 3' overhangs serves multiple functions: efficient RISC loading, potential for multi-mRNA targeting, and minimal immune activation, making the design universally applicable across different therapeutic contexts.
4Ease of manufacture
If blunt-ended dsRNA is used for simplicity, then manufacturing is easier, but immune recognition increases leading to interferon activation
Solution Approach 1:
The patent applies parameter changes by modifying the end-structure parameters of dsRNA from blunt ends to 3' overhangs of 1-5 nucleotides. This single structural parameter change significantly reduces immune recognition while remaining compatible with standard solid-phase synthesis methods, maintaining ease of manufacture while eliminating the harmful immune activation effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ldRNAs effectively inhibit gene expression with minimal induction of antiviral responses, achieving potent silencing of target genes while avoiding immune activation, even in immune-sensitive cell lines, and can target multiple mRNA sequences with high specificity and efficiency.
Implementation Method 1
The RNAi pathway is initiated by the Dicer endonuclease, which cleaves long dsRNAs into short interfering RNA (siRNA) fragments
Implementation Method 2
Post-transcriptional gene silencing occurs when an antisense sequence in the guide strand pairs with a complementary sequence in a mRNA and induces cleavage
Data Source
AI summary
The present technology relates, in part, to long double-stranded RNA (dsRNA) (e.g., 30 or more base pairs) that inhibits gene expression.